1. Home
  2. RMCO vs NSPR Comparison

RMCO vs NSPR Comparison

Compare RMCO & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

HOLD

Current Price

$2.25

Market Cap

37.9M

Sector

Miscellaneous

ML Signal

HOLD

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.67

Market Cap

33.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCO
NSPR
Founded
2021
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Medical/Dental Instruments
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
33.7M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
RMCO
NSPR
Price
$2.25
$0.67
Analyst Decision
Buy
Buy
Analyst Count
1
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
6.8K
54.8K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
0.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,310,000.00
Revenue This Year
$209.10
$57.98
Revenue Next Year
$133.33
$95.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.28
$0.63
52 Week High
$5.00
$2.93

Technical Indicators

Market Signals
Indicator
RMCO
NSPR
Relative Strength Index (RSI) 43.90 38.95
Support Level $2.11 $0.63
Resistance Level $2.62 $0.72
Average True Range (ATR) 0.17 0.03
MACD 0.01 0.01
Stochastic Oscillator 28.68 46.09

Price Performance

Historical Comparison
RMCO
NSPR

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: